Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize
- Awarded in recognition of excellence in research and innovation and contribution to scientific progress
- Reflects the revolutionary potential of Curve’s gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targets
Southampton, UK, 25 June 2025 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and small molecule drugs to address high priority intracellular disease targets, today proudly announces that Professor Ali Tavassoli, its Co-Founder and Chief Scientific Officer, has been awarded the Interdisciplinary Prize by the Royal Society of Chemistry in recognition of his brilliance in research and innovation, and contribution to scientific progress.
